Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed grade I, II or III endometrial adenocarcinoma (endometrioid, villoglandular, mucinous, adenosquamous, papillary serous, clear cell, or not otherwise specified)
• Must have had total hysterectomy and bilateral salpingo-oophorectomy within past 20 weeks
• * Surgical stage IA, IB, IC, IIA (occult), or IIB (occult) disease
• Must have had normal mammogram, or a negative breast biopsy after an abnormal mammogram, within past year
• PATIENT CHARACTERISTICS:
• Age:
• Not specified
• Performance status:
• Not specified
• Life expectancy:
• Not specified
• Hematopoietic:
• Not specified
• Hepatic:
• Bilirubin no greater than 1.5 times normal
• SGOT no greater than 3 times normal
• No acute liver disease
• Renal:
• Not specified
• Cardiovascular:
• No prior thromboembolic disease
• Other:
• No prior or current carcinoma of the breast
• No other prior invasive malignancy within the past 5 years except nonmelanoma skin cancer
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• Not specified
• Chemotherapy:
• Not specified
• Endocrine therapy:
• No concurrent hormonal therapy
• Radiotherapy:
• Not specified
• Surgery:
• See Disease Characteristics
• Recovered from prior surgery
• Other:
• No prior cancer treatment that would preclude study therapy
• Concurrent participation on GOG Lap-1 or GOG Lap-2 allowed